Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$12.90
-0.44-3.30%
al cierre: -
$12.90
0.000.00%
After hour: 5:20 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
10x Genomics Inc ha un obiettivo di prezzo di consenso pari a $20.62, stabilito in base alle ultime valutazioni degli analisti di 19. Le ultime 3 valutazioni degli analisti sono state rilasciate da Piper Sandler, Morgan Stanley y UBS il septiembre 11, 2025, agosto 12, 2025 y agosto 8, 2025. Con un obiettivo di prezzo medio di $15 tra le Piper Sandler, Morgan Stanley y UBS, c'è un implicito 16.28% upside per 10x Genomics Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Piper Sandler
Morgan Stanley
UBS
Barclays
B of A Securities
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para 10x Genomics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
09/11/2025 | 16.28% | Piper Sandler | → $15 | Initiates | → Neutral | |||
08/12/2025 | 31.78% | Morgan Stanley | $18 → $17 | Maintains | Overweight | |||
08/08/2025 | 0.78% | UBS | $12 → $13 | Maintains | Neutral | |||
08/08/2025 | 16.28% | Barclays | $13 → $15 | Maintains | Overweight | |||
06/26/2025 | 0.78% | B of A Securities | $12 → $13 | Maintains | Neutral | |||
06/24/2025 | 0.78% | Barclays | $12 → $13 | Maintains | Overweight | |||
05/19/2025 | 39.53% | Morgan Stanley | $26 → $18 | Maintains | Overweight | |||
05/15/2025 | 8.53% | Stephens & Co. | $14 → $14 | Reiterates | Overweight → Overweight | |||
05/13/2025 | -6.98% | UBS | $14 → $12 | Maintains | Neutral | |||
05/12/2025 | -49.61% | Goldman Sachs | $7.5 → $6.5 | Maintains | Sell | |||
05/12/2025 | 16.28% | Canaccord Genuity | $18 → $15 | Maintains | Buy | |||
05/09/2025 | -30.23% | JP Morgan | $12 → $9 | Maintains | Neutral | |||
04/10/2025 | -6.98% | Barclays | $15 → $12 | Maintains | Overweight | |||
03/04/2025 | 16.28% | Citigroup | $20 → $15 | Maintains | Buy | |||
02/14/2025 | 101.55% | Morgan Stanley | $28 → $26 | Maintains | Overweight | |||
02/14/2025 | 16.28% | Barclays | $18 → $15 | Maintains | Overweight | |||
02/13/2025 | 39.53% | Canaccord Genuity | $20 → $18 | Maintains | Buy | |||
02/13/2025 | 55.04% | Citigroup | $23 → $20 | Maintains | Buy | |||
02/13/2025 | -6.98% | JP Morgan | $14 → $12 | Maintains | Neutral | |||
02/13/2025 | 8.53% | UBS | $20 → $14 | Maintains | Neutral | |||
02/13/2025 | 39.53% | Stifel | $21 → $18 | Maintains | Buy | |||
02/13/2025 | -6.98% | Leerink Partners | $25 → $12 | Downgrade | Outperform → Market Perform | |||
02/10/2025 | 39.53% | Barclays | $19 → $18 | Maintains | Overweight | |||
01/13/2025 | 117.05% | Morgan Stanley | $30 → $28 | Maintains | Overweight | |||
11/01/2024 | 47.29% | Barclays | $21 → $19 | Maintains | Overweight | |||
10/30/2024 | 78.29% | Citigroup | $35 → $23 | Maintains | Buy | |||
10/30/2024 | 8.53% | Goldman Sachs | $16 → $14 | Maintains | Sell | |||
10/30/2024 | 8.53% | JP Morgan | $20 → $14 | Maintains | Neutral | |||
10/30/2024 | 55.04% | UBS | $25 → $20 | Maintains | Neutral | |||
10/15/2024 | 62.79% | Barclays | $24 → $21 | Maintains | Overweight | |||
10/10/2024 | 132.56% | Stephens & Co. | $30 → $30 | Reiterates | Overweight → Overweight | |||
10/10/2024 | 55.04% | Canaccord Genuity | $32 → $20 | Maintains | Buy | |||
09/04/2024 | 132.56% | Stephens & Co. | $30 → $30 | Reiterates | Overweight → Overweight | |||
09/03/2024 | 171.32% | Leerink Partners | → $35 | Initiates | → Outperform | |||
08/13/2024 | 93.8% | UBS | $30 → $25 | Maintains | Neutral | |||
08/13/2024 | 256.59% | Morgan Stanley | $50 → $46 | Maintains | Overweight | |||
07/23/2024 | 148.06% | Canaccord Genuity | $50 → $32 | Maintains | Buy | |||
07/22/2024 | 86.05% | Jefferies | $24 → $24 | Upgrade | Hold → Buy | |||
07/18/2024 | 93.8% | B of A Securities | $36 → $25 | Maintains | Neutral | |||
07/18/2024 | 55.04% | JP Morgan | $40 → $20 | Downgrade | Overweight → Neutral | |||
07/16/2024 | 93.8% | Stifel | $53 → $25 | Maintains | Buy | |||
07/10/2024 | 93.8% | Deutsche Bank | $55 → $25 | Downgrade | Buy → Hold | |||
07/09/2024 | 24.03% | Goldman Sachs | $26 → $16 | Maintains | Sell | |||
06/28/2024 | 86.05% | Barclays | $36 → $24 | Maintains | Overweight | |||
06/27/2024 | — | Wolfe Research | — | Downgrade | Outperform → Peer Perform | |||
06/26/2024 | — | Guggenheim | — | Downgrade | Buy → Neutral | |||
06/25/2024 | — | Guggenheim | — | Downgrade | Buy → Neutral | |||
06/03/2024 | 86.05% | Jefferies | → $24 | Initiates | → Hold | |||
05/01/2024 | 132.56% | UBS | $52 → $30 | Maintains | Neutral | |||
05/01/2024 | 179.07% | B of A Securities | $45 → $36 | Maintains | Neutral | |||
05/01/2024 | 101.55% | Goldman Sachs | $30 → $26 | Maintains | Sell | |||
05/01/2024 | 148.06% | TD Cowen | $57 → $32 | Downgrade | Buy → Hold | |||
05/01/2024 | 310.85% | Stifel | $63 → $53 | Maintains | Buy | |||
04/29/2024 | 287.6% | Canaccord Genuity | $65 → $50 | Maintains | Buy | |||
04/18/2024 | 326.36% | Deutsche Bank | $60 → $55 | Maintains | Buy | |||
04/10/2024 | 248.84% | Barclays | $55 → $45 | Maintains | Overweight | |||
02/16/2024 | 388.37% | Stifel | $68 → $63 | Maintains | Buy | |||
01/25/2024 | 326.36% | Barclays | $45 → $55 | Maintains | Overweight | |||
12/14/2023 | 365.12% | Guggenheim | → $60 | Initiates | → Buy | |||
12/13/2023 | — | Wolfe Research | — | Initiates | → Outperform | |||
12/12/2023 | 318.6% | B of A Securities | $36 → $54 | Upgrade | Underperform → Neutral | |||
09/29/2023 | 264.34% | Barclays | $66 → $47 | Maintains | Overweight | |||
09/19/2023 | 442.64% | Canaccord Genuity | → $70 | Reiterates | Buy → Buy | |||
08/07/2023 | 403.88% | Morgan Stanley | $65 → $65 | Reiterates | Overweight → Overweight | |||
08/04/2023 | 411.63% | Barclays | $65 → $66 | Maintains | Overweight | |||
08/04/2023 | 481.4% | Citigroup | $65 → $75 | Maintains | Buy | |||
07/13/2023 | 132.56% | Goldman Sachs | $25 → $30 | Maintains | Sell | |||
05/18/2023 | 403.88% | Stephens & Co. | → $65 | Reiterates | Overweight → Overweight | |||
05/10/2023 | 403.88% | Barclays | → $65 | Initiates | → Overweight | |||
05/04/2023 | 427.13% | Stifel | $57 → $68 | Maintains | Buy | |||
05/04/2023 | 411.63% | TD Cowen | $62 → $66 | Maintains | Outperform | |||
05/04/2023 | 403.88% | Canaccord Genuity | $58 → $65 | Maintains | Buy | |||
05/04/2023 | 403.88% | Stephens & Co. | → $65 | Reiterates | → Overweight | |||
03/31/2023 | 403.88% | Stephens & Co. | → $65 | Initiates | → Overweight | |||
02/16/2023 | 403.88% | Morgan Stanley | $64 → $65 | Maintains | Overweight | |||
02/16/2023 | 349.61% | Canaccord Genuity | $55 → $58 | Maintains | Buy | |||
02/16/2023 | 341.86% | Cowen & Co. | $52 → $57 | Maintains | Outperform | |||
02/02/2023 | 287.6% | UBS | → $50 | Initiates | → Neutral | |||
12/14/2022 | 287.6% | Deutsche Bank | → $50 | Initiates | → Buy | |||
11/04/2022 | 396.12% | Morgan Stanley | $70 → $64 | Maintains | Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de 10x Genomics (TXG)?
El último precio objetivo de 10x Genomics (NASDAQ:TXG) fue comunicado por Piper Sandler el septiembre 11, 2025. La firma de analistas fijó un precio objetivo para $15.00 que espera TXG a rise dentro de 12 meses (un posible 16.28% upside). 29 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre 10x Genomics (TXG)?
La última calificación de analistas para 10x Genomics (NASDAQ:TXG) fue proporcionada por Piper Sandler, y 10x Genomics iniciado su neutral calificación.
¿Cuándo se produjo la última revisión al alza de 10x Genomics (TXG)?
La última revisión al alza de 10x Genomics Inc se produjo en julio 22, 2024, cuando Jefferies elevó su precio objetivo a $24. Jefferies anteriormente tenía a hold para 10x Genomics Inc.
¿Cuándo fue la última revisión a la baja de 10x Genomics (TXG)?
La última revisión a la baja de 10x Genomics Inc se produjo en febrero 13, 2025, cuando Leerink Partners cambió su precio objetivo de $25 a $12 para 10x Genomics Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para 10x Genomics (TXG)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de 10x Genomics, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de 10x Genomics se registró el septiembre 11, 2025, por lo que la próxima calificación estará disponible en torno al septiembre 11, 2026.
¿Es correcta la calificación de los analistas sobre 10x Genomics (TXG)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de 10x Genomics (TXG) fue un iniciado con un precio objetivo de $0.00 a $15.00. El precio actual al que cotiza 10x Genomics (TXG) es de $12.90, que es within del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.